Antineoplastics
1
Reactions 1407 - 23 Jun 2012 S Antineoplastics Neutropenia: case report A 58-year-old woman with chronic kidney disease developed neutropenia during treatment with FOLFIRI [irinotecan, folinic acid and fluorouracil] and bevacizumab for metastatic colon cancer. The woman had been diagnosed with colon cancer in 2006, and recurrent disease in July 2009. After discovery of ovarian metastases, in June 2010 the woman began receiving FOLFIRI at a 70% dose with bevacizumab [routes and dosages not stated] every 2 weeks on non- haemodialysis days. After 2 cycles, she had developed grade 4 neutropenia. Chemotherapy was withheld and the woman received granulocyte colony stimulating factors. She improved, and FOLFIRI/bevacizumab was subsequently restarted at a 60% dosage. She had no further adverse events except grade 3 haemoglobin decreases. She received a total of 21 cycles. Author comment: "We then changed the regimen to FOLFIRI (70% dose)/bevacizumab (BV). Neutropenia (grade 4) was observed after the second treatment." Kuwabara H, et al. mFOLFOX6 and FOLFIRI/bevacizumab treatment in a patient on hemodialysis with metastatic colon cancer. Gan to Kagaku Ryoho 38: 2250-2, No. 12, Nov 2011 [Japanese; summarised from a translation] - Japan 803072450 1 Reactions 23 Jun 2012 No. 1407 0114-9954/10/1407-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 1407 - 23 Jun 2012
SAntineoplastics
Neutropenia: case reportA 58-year-old woman with chronic kidney disease
developed neutropenia during treatment with FOLFIRI[irinotecan, folinic acid and fluorouracil] and bevacizumabfor metastatic colon cancer.
The woman had been diagnosed with colon cancer in2006, and recurrent disease in July 2009. After discovery ofovarian metastases, in June 2010 the woman beganreceiving FOLFIRI at a 70% dose with bevacizumab [routesand dosages not stated] every 2 weeks on non-haemodialysis days. After 2 cycles, she had developedgrade 4 neutropenia.
Chemotherapy was withheld and the woman receivedgranulocyte colony stimulating factors. She improved, andFOLFIRI/bevacizumab was subsequently restarted at a 60%dosage. She had no further adverse events except grade 3haemoglobin decreases. She received a total of 21 cycles.
Author comment: "We then changed the regimen toFOLFIRI (70% dose)/bevacizumab (BV). Neutropenia (grade 4)was observed after the second treatment."Kuwabara H, et al. mFOLFOX6 and FOLFIRI/bevacizumab treatment in a patienton hemodialysis with metastatic colon cancer. Gan to Kagaku Ryoho 38: 2250-2,No. 12, Nov 2011 [Japanese; summarised from a translation] - Japan 803072450
1
Reactions 23 Jun 2012 No. 14070114-9954/10/1407-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
